What We're Reading: Page 216
Industry reads hand-picked by our editors
Oct 01, 2019
-
The Wall Street Journal
Novel Plan Aims to Settle Opioid Suits
-
Reuters
Bayer to spend over 25 billion euros in crop science R&D over 10 years
-
FiercePharma
Big Pharma CEOs' Chinese names: Here's how they look and what they mean
Sep 30, 2019
-
Bloomberg
Future of Genetically Modified Babies May Lie in Putin's Hands
-
The Washington Post
‘Out here, it’s just me’: In the medical desert of rural America, one doctor for 11,000 square miles
-
Reuters
French drugmaker Sanofi to cut around 200 jobs in Japan - source
-
STAT
Error undermines controversial study related to CRISPR babies experiment
Sep 27, 2019
Sep 26, 2019
-
The Wall Street Journal
Health-Care Investor to Build Biotech Labs in Nomad
-
The Washington Post
Shuping Wang, whistleblower who exposed China's HIV/AIDS crisis, dies at 59
-
The Independent
Labour would found state drug company to make medicines cheaper
-
Bloomberg
Takeda Is Close to Selling Emerging Market, European Drugs
Sep 25, 2019
-
Vantage
Does amount matter when it comes to a biotech IPO?
-
The Washington Post
Why the cancer ‘moonshot’ has been so disappointing
-
The Wall Street Journal
A Big Biotech Bet Hiding in Plain Sight
Sep 24, 2019
Sep 23, 2019
-
CNN
Opioid-maker Purdue Pharma is allowed bonus payout in bankruptcy case
-
Endpoints
Genentech submits a big plan to expand its South San Francisco footprint
-
Financial Times
New allies fight Africa's deadly scourge of fake medicines
-
The Washington Post
As off-label use spreads for lifesaving niche drugs, supplies grow scarce, leaving patients in the lurch
Previous
